Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This pump and dump was .06 in 2011 and closed at .39 today. That's a nice slow pump with a 600% return in four years. Sorry that doesn't meet your high standards for an investment. I'll take it myself.
This pump and dump was .06 in 2011 and closed at .39 today. That's a nice slow pump with a 600% return in four years. Sorry that doesn't meet your high standards for an investment. I'll take it myself.
Mr Skydog526...
As a retail investor in ELTP since 2004 let me tell you that NH has been nothing short of an ATM .... to me.
Mr Hakim's efforts have thus far paid off all of my car loans and half of my mortgage despite my very imperfect trading decisions.
Should he succeed in getting ELI-200 to market...with several more NDA's to follow he will fund my early retirement.
I'm laughing all the way.
Warmest Regards,
Hike
I'd like more actually. Thanks in advance.
http://club.ino.com/trend/analysis/equity/NASDAQ_ELTP/trendanalysis?ticket=7b6f869c9bg06a08c08c07008806c&id=2CC5A3
Smart Scan Analysis for ELTP
Based on a pre-defined weighted trend formula for chart analysis, ELTP scored +100 on a scale from -100 (strong downtrend) to +100 (strong uptrend).
So the stock may go up or it may go down?
Nope that's a fact
Neither are opinions provided without ...any evidence
Ok so no links given in support of your assertions ... Got it.
No it's not
Ummm, they aren't on Nasdaq now so it would be pretty hard for them to "stay" on the Nasdaq.
100/1?
Sigh....
"It is difficult to generalise, but on the whole P<0.01 would normally be considered significant and P<0.001 highly significant."
http://www.numberwatch.co.uk/significance.htm
Yes. Very informative site.
Team Against Opioid Abuse
http://www.teamagainstopioidabuse.com/
Slapped it for 100,000 shares.
Ask = 0.230 x498,000
Seriously?
You provided the link yourself!
I am quite savvy thanks. Not concerned at all.
So lets recap.
Novel we made money and the money we got is funding ELI-200 development.
Epic is giving us $15,000 in milestone payments to fund ELI-200 and then some.
No one has proved the beads can be separated. Only wild theories. HAL studies proved otherwise. The FDA will go by the HAL studies, not message board theories.
Novel gate? Elite made money on that deal ... Epic gate ? Epic is providing $15 million plus? Bunion gate... you mean the phase three study the FDA approved the protocol for? Bead gate...what is that? I don't find these arguments compelling at all.
he only similarities between the agonist bead and the antagonist bead are size, color, weight, and density....
IPCI is very interesting. On one hand they have yet to go beyond Phase I with Rexista, yet the FDA has apparently given them the path to bypass Phase III. IPCI's low market cap of $51,000,000 makes it an interesting play in and of itself. Yet stock was $3.38 when FDA announced fast track OK...and today is $2.15. Elite has been through multiple Phase 1, 2, 3 (soon!), HAL, BE, etc studies...
Apparently some can't differentiate between "abuse-proof" and "abuse-deterrent"
I'm sure if someone with enough time, money and resources wants to defeat Elite's formulation they could.
How much time energy or resources does the average junkie have?
Not much. Hence deterrence is more than sufficient.
Name one "abuse proof" formulation.
Just cut and pasted from the transcript, didn't suggest a thing. I think when you register for these calls you have a spot to indicate your company. If you don't indicate one or indicate "individual investor" the transcripts indicate "unidentified analyst". If you indicate a company the transcripts indicate you as "Analyst - Company Name". It's just a flaw in the workflow.
IMO. Nothing to get up in arms over. Still better than Sally.
Yes, that's a terrible thing that an experienced investment advisor and Executive Director of an investment advisory firm thinks highly enough of little old Elite to call in to their conference call. It's a big step up from Sally!
http://www.evaluategroup.com/Pharma/ViewStoryEPVantage.aspx?AlertStory=true&storyId=573951
Abuse trial win reanimates Remoxy
Source EP Vantage
Company Pain Therapeutics, Pfizer, Purdue Pharma
Tags Comment, Company Strategy, Trial Results, Central Nervous System, Free Content
Date May 13, 2015
No one likes Remoxy – and for once that’s a good thing. Pain Therapeutics’ troubled opioid was significantly less appealing to recreational drug users than an immediate-release version in a clinical trial, and the company is to resubmit a US approval application at the beginning of next year. Its stock jumped 35% yesterday as a result.
Even so, the shares are still down 37% from October 24, a day before Pfizer handed back rights to the abuse-deterrent oxycodone formulation. These data are a good sign, but Pain has some way to go if it is to convince the FDA that Remoxy merits approval under the strict guidelines governing opioids.
The trial, conducted under Pfizer’s auspices as its last act before the licence was terminated, was geared towards proving that Remoxy deters abuse. The FDA has in the past said it will not approve new opioids unless they can prove they are resistant to being crushed or dissolved – or that, if they are, they do not produce a high. The study’s design was discussed with the FDA and conducted in accordance with the agency’s draft guidance to industry.
Nearly 60 healthy, non-dependent recreational opioid users completed the randomised, double-blind trial. They were instructed to chew 40mg Remoxy capsules, 40mg immediate-release oxycodone and placebo pills vigorously for up to five minutes.
Pain Therapeutics said that none was able to chew Remoxy for the specified time, thanks to its taste, texture or high viscosity.
No one likes us, we don’t care
The co-primary endpoints were drug liking and drug high for intact and chewed Remoxy compared with immediate-release oxycodone; both were met with statistical significance.
Secondary endpoints included good drug effects (significantly lower for Remoxy versus immediate-release oxycodone) and bad drug effects (significantly higher for Remoxy). On pupil constriction, nausea and feeling sick, scores were significantly lower for Remoxy compared with IR oxycodone.
The future of the project, and of Pain Therapeutics itself, depends on what the FDA makes of it. The regulator has already rejected it twice, in 2008 and 2011, and can be very strict when it comes to opioids.
And there is already a form of oxycodone on the US market that the FDA does consider abuse-deterrent – Purdue Pharma’s OxyContin. Even if the FDA is won over by Remoxy on the third try, it will be hard to forecast its market performance against a similar and more established product.
And first the company must at least get its lead asset re-submitted. The firm believes that no more clinical trials will be needed, but its chief executive, Remi Barbier, acknowledged on a conference call yesterday that “a little bit of in vitro work” remained to be done. Its finance chief, Peter Roddy, said the company’s roughly $40m cash would see it through to this point, and said about $12m would be spent this year.
The company is also working on other programmes, foremost of which is Fenrock, a transdermal patch formulation of fentanyl also designed to be abuse-resistant. Pain hopes to have preclinical proof of concept data on the project “sometime over the next few weeks”, Mr Barbier said.
It will also unveil an entirely new candidate later this year, perhaps in the third quarter. This targets a large, underserved, chronic non-pain CNS market, Mr Barbier said.
Pain will need more money for these projects. Its existing cash should take Fenrock to clinical proof of concept but not all the way to approval, and as for the undisclosed project the company is working on a new non-dilutive source of funding that should enable an IND filing. But all this is pretty vague and seems unlikely to have contributed to yesterday’s share ramp.
It is not surprising that the company is also very open to takeover offers, but with only one late-stage clinical prospect potential buyers are likely to wait for Remoxy’s approval – if, indeed, it comes.
To contact the writer of this story email Elizabeth Cairns in London at elizabethc@epvantage.com or follow @LizEPVantage on Twitter
Relates to this from last 10Q:
10.82** January 19, 2015 Second Amendment to TPN-Elite Manufacturing and Supply Agreement dated June 23, 2011 and First
Amendment to the TPN-Elite Manufacturing and Supply Agreement dated September 21, 2012. . Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Equilar Atlas Email Alert
March 10, 2015
Updates on 1 companies, 6 individuals
.
Elite Pharmaceuticals, Inc. (ELTP)
New Equity Award (3/5/2015)
Barry H. Dash Ph.D., Board Member $14.8 K
Nasrat A. Hakim, President and CEO $517.8 K
Jeenarine Narine, Board Member $14.8 K
Ashok G. Nigalaye Ph.D., Dir. and CFO $14.8 K
Jerry I. Treppel, Chairman of the Board $22.2 K
Carter Julian Ward, CFO, Secretary and Treasurer $22.2 K
http://www.b2i.cc/b2iContent/2258/20091118140510_0218.mp3
Online recording of previous conference call.
http://www.businesswire.com/news/home/20150225005372/en/Teva-Announces-FDA-Acceptance-Review-NDA-Investigational#.VO3gqvnF87l
Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets with Proprietary Abuse Deterrence Technology
Crazy huh?
ELTP thinks they are on OTCBB but....
Our common stock is currently quoted on the Over-the-Counter Bulletin Board, or the OTCBB, under the symbol “ELTP”.
http://www.sec.gov/Archives/edgar/data/1053369/000114420414041960/v383403_424b3.htm
Yes that was the share price when he took over. It's more than triple that today. Impressive job by Nasrat no?
The CEO invested a boatload of ANDA's that he owned for which he now has preferred shares instead in ELTP. Those preferred shares represent over 140,000,000 common shares.
Prior to joining ELTP as CEO he bought 11,000,000+ shares with his own money, doesn't take a salary except in shares.
He recently bought 700,000+ shares on the open market in his IRA.
And you say he "didn't buy more" ??
Really?
CC is on Wednesday.
As I called it.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110809579
Couldn't be Monday due to holiday.